Login / Register
MS Validated Antibodies GmbH
  • About us
  • Products
    • Primary antibodies
    • Gallery
  • Distributors
  • Validation
  • Publications
    • Large Scale Studies
    • Further Publications
  • Contact
  • About us
  • Products
    • Primary antibodies
    • Gallery
  • Distributors
  • Validation
  • Publications
    • Large Scale Studies
    • Further Publications
  • Contact
×

Cancer Tissue Gallery INSM1

Path Created with Sketch.
Go to INSM1 Normal Tissue GalleryGo back to Product Page
Adrenal gland – INSM1 negative adrenocortical adenoma.
Adrenal gland - INSM1 negative adrenocortical adenoma.
Adrenal gland – INSM1 negative adrenocortical carcinoma.
Adrenal gland - INSM1 negative adrenocortical carcinoma.
Adrenal gland – Pheochromocytoma showing moderate to strong INSM1 immunostaining in tumor cells.
Adrenal gland - Pheochromocytoma showing moderate to strong INSM1 immunostaining in tumor cells.
Colon – Colorectal adenocarcinoma showing moderate to strong INSM1 immunostaining in a fraction of cells (30-50%).
Colon - Colorectal adenocarcinoma showing moderate to strong INSM1 immunostaining in a fraction of cells (30-50%).
Esophagus – INSM1 negative adenocarcinoma.
Esophagus - INSM1 negative adenocarcinoma.
Esophagus – Squamous cell carcinoma showing weak INSM1 immunostaining in a small fraction of cells (<5%).
Esophagus - Squamous cell carcinoma showing weak INSM1 immunostaining in a small fraction of cells (<5%).
Ileum – Neuroendocrine tumor showing moderate INSM1 immunostaining in tumor cells.
Ileum - Neuroendocrine tumor showing moderate INSM1 immunostaining in tumor cells.
Kidney – INSM1 negative clear cell renal cell carcinoma.
Kidney - INSM1 negative clear cell renal cell carcinoma.
Kidney – INSM1 negative papillary renal cell carcinoma.
Kidney - INSM1 negative papillary renal cell carcinoma.
Larynx – INSM1 negative squamous cell carcinoma.
Larynx - INSM1 negative squamous cell carcinoma.
Liver – INSM1 negative cholangiocellular carcinoma.
Liver - INSM1 negative cholangiocellular carcinoma.
Liver – INSM1 negative hepatocellular carcinoma.
Liver - INSM1 negative hepatocellular carcinoma.
Lung – INSM1 negative adenocarcinoma.
Lung - INSM1 negative adenocarcinoma.
Lung – Neuroendocrine tumor with strong INSM1 positivity of tumor cells.
Lung - Neuroendocrine tumor with strong INSM1 positivity of tumor cells.
Lung – Small cell neuroendocrine carcinoma showing strong INSM1 immunostaining in most tumor cells.
Lung - Small cell neuroendocrine carcinoma showing strong INSM1 immunostaining in most tumor cells.
Lymph node – Diffuse large B-cell lymphoma showing a weak to moderate INSM1 immunostaining in a fraction of cells (>50%).
Lymph node - Diffuse large B-cell lymphoma showing a weak to moderate INSM1 immunostaining in a fraction of cells (>50%).
Ovary – Endomeroid carcinoma showing a weak to moderate INSM1 immunostaining in tumor cells.
Ovary - Endomeroid carcinoma showing a weak to moderate INSM1 immunostaining in tumor cells.
Pancreas – INSM1 negative acinar cell carcinoma.
Pancreas - INSM1 negative acinar cell carcinoma.
Pancreas – Neuroendocrine tumor showing strong INSM1 immunostaining in tumor cells.
Pancreas - Neuroendocrine tumor showing strong INSM1 immunostaining in tumor cells.
Pharynx – Squamous cell carcinoma showing moderate INSM1 immunostaining in a fraction of tumor cells (20-30%).
Pharynx - Squamous cell carcinoma showing moderate INSM1 immunostaining in a fraction of tumor cells (20-30%).
Pharynx – Squamous cell carcinoma showing moderate to strong INSM1 immunostaining in a fraction of tumor cells (30-50%).
Pharynx - Squamous cell carcinoma showing moderate to strong INSM1 immunostaining in a fraction of tumor cells (30-50%).
Prostate – INSM1 negative adenocarcinoma (Gleason 3+3=6).
Prostate - INSM1 negative adenocarcinoma (Gleason 3+3=6).
Prostate – Small cell neuroendocrine carcinoma exhibiting strong INSM1 immunostaining in tumor cells.
Prostate - Small cell neuroendocrine carcinoma exhibiting strong INSM1 immunostaining in tumor cells.
Salivary gland – INSM1 negative pleomorphic adenoma.
Salivary gland - INSM1 negative pleomorphic adenoma.
Skin – INSM1 negative malignant melanoma.
Skin - INSM1 negative malignant melanoma.
Skin – Merkel cell carcinoma with strong INSM1 positivity of tumor cells.
Skin - Merkel cell carcinoma with strong INSM1 positivity of tumor cells.
Stomach – INSM1 negative gastric adenocarcinoma.
Stomach - INSM1 negative gastric adenocarcinoma.
Stomach – INSM1 negative gastrointestinal stromal tumor (GIST).
Stomach - INSM1 negative gastrointestinal stromal tumor (GIST).
Testis – INSM1 negative seminoma.
Testis - INSM1 negative seminoma.
Thymus – INSM1 negative thymoma containing some residual INSM1 positive thymic epithelial cells.
Thymus - INSM1 negative thymoma containing some residual INSM1 positive thymic epithelial cells.
Thyroid – INSM1 negative papillary carcinoma.
Thyroid - INSM1 negative papillary carcinoma.
Thyroid – Medullary carcinoma showing moderate to strong INSM1 immunostaining. Adjacent normal thyroid follicles are INSM1 negative.
Thyroid - Medullary carcinoma showing moderate to strong INSM1 immunostaining. Adjacent normal thyroid follicles are INSM1 negative.
Urinary bladder – INSM1 negative muscle-invasive urothelial carcinoma.
Urinary bladder - INSM1 negative muscle-invasive urothelial carcinoma.
Urinary bladder – Small cell neuroendocrine carcinoma exhibiting strong INSM1 positivity in tumor cells.
Urinary bladder - Small cell neuroendocrine carcinoma exhibiting strong INSM1 positivity in tumor cells.
Uterus – INSM1 negative endometroid carcinoma of the endometrium.
Uterus - INSM1 negative endometroid carcinoma of the endometrium.
  • Linkedin
  • My Account
  • Search
    ×
  • Cart 0
© 2023 MS Validated Antibodies
  • Imprint
  • Privacy Policy
  • Distributors